Amneal Pharmaceuticals announces the US launch of BORUZU, a presentation of bortezomib for subcutaneous administration or IV administration. As a ready-to-use oncology product, it can reduce the compounding preparation steps typically required with administration. BORUZU (bortezomib injection) is a proteasome inhibitor used for the treatment of multiple myeloma and mantle cell lymphoma. The product references the branded product Velcade, a lyophilized powder requiring reconstitution before use.